Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.

Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators.

Arthritis Rheumatol. 2015 May;67(8):2011-9. doi: 10.1002/art.39169. Erratum in: Arthritis Rheumatol. 2015 Nov;67(11):3096.

2.

Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.

Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, Sarzi-Puttini P, Emery P, Barrett JH, Morgan AW, McDermott MF.

Ann Rheum Dis. 2014 Jun;73(6):1202-10. doi: 10.1136/annrheumdis-2013-203276. Epub 2013 May 17.

PMID:
23687262
3.

High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis.

Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C, Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate; Wellcome Trust Case Control Consortium, Concannon P, Onengut-Gumuscu S, Rich SS, Deloukas P, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Ärlsetig L, Martin J, Rantapää-Dahlqvist S, Plenge RM, Raychaudhuri S, Klareskog L, Gregersen PK, Worthington J.

Nat Genet. 2012 Dec;44(12):1336-40. doi: 10.1038/ng.2462. Epub 2012 Nov 11.

4.

Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis.

Fisher BA, Plant D, Lundberg K, Charles P, Barton A, Venables PJ; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS).

J Rheumatol. 2012 May;39(5):929-32. doi: 10.3899/jrheum.111315. Epub 2012 Apr 1.

PMID:
22467927
5.

Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci.

Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD; Wellcome Trust Case Control Consortium; British Society for Rheumatology Biologics Register, Barton A.

Arthritis Rheum. 2011 Mar;63(3):645-53. doi: 10.1002/art.30130.

6.

Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.

Hassan B, Maxwell JR, Hyrich KL; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG.

Rheumatology (Oxford). 2010 Jan;49(1):43-7. doi: 10.1093/rheumatology/kep372. Epub 2009 Nov 19.

PMID:
19926672
7.

Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients.

Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, Morgan AW, Wilson AG, Isaacs JD, Worthington J, Barton A; BRAGGSS.

Pharmacogenet Genomics. 2009 Apr;19(4):319-23. doi: 10.1097/FPC.0b013e328328d51f.

PMID:
19262425
8.

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.

Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, Thomson W, Worthington J, Emery P, Morgan AW, Wilson AG, Isaacs J, Barton A; BRAGGSS.

Ann Rheum Dis. 2009 Jan;68(1):69-74. doi: 10.1136/ard.2007.084715. Epub 2008 Mar 28. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

9.

What factors influence functional ability in patients with rheumatoid arthritis. Do they alter over time?

Plant MJ, O'Sullivan MM, Lewis PA, Camilleri JP, Coles EC, Jessop JD.

Rheumatology (Oxford). 2005 Sep;44(9):1181-5. Epub 2005 Jun 21.

PMID:
15972357
10.

Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium.

Choy EH, Scott DL, Kingsley GH, Williams P, Wojtulewski J, Papasavvas G, Henderson E, Macfarlane D, Erhardt C, Young A, Plant MJ, Panayi GS.

Clin Exp Rheumatol. 2002 May-Jun;20(3):351-8.

PMID:
12102471
11.

Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis.

Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD.

Arthritis Rheum. 2000 Jul;43(7):1473-7.

12.

The influence of HLA-DRB1 alleles encoding the DERAA amino acid motif on radiological outcome in rheumatoid arthritis.

Mattey DL, Hassell AB, Plant MJ, Cheung NT, Dawes PT, Jones PW, Thomson W, Poulton KV, Hajeer AH, Ollier WE.

Rheumatology (Oxford). 1999 Dec;38(12):1221-7.

PMID:
10587549
13.

A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis.

Jessop JD, O'Sullivan MM, Lewis PA, Williams LA, Camilleri JP, Plant MJ, Coles EC.

Br J Rheumatol. 1998 Sep;37(9):992-1002.

PMID:
9783766
14.

Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study.

Plant MJ, Jones PW, Saklatvala J, Ollier WE, Dawes PT.

J Rheumatol. 1998 Mar;25(3):417-26.

PMID:
9517757
15.

Radiographic patterns and response to corticosteroid hip injection.

Plant MJ, Borg AA, Dziedzic K, Saklatvala J, Dawes PT.

Ann Rheum Dis. 1997 Aug;56(8):476-80.

16.

Management of oral complications of disease-modifying drugs in rheumatoid arthritis.

Carpenter EH, Plant MJ, Hassell AB, Shadforth MF, Fisher J, Clarke S, Hothersall TE, Dawes PT.

Br J Rheumatol. 1997 Apr;36(4):473-8.

PMID:
9159543
17.

Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival.

Wilkie ME, Plant MJ, Edwards L, Brown CB.

Perit Dial Int. 1997 Jan-Feb;17(1):84-7. No abstract available.

PMID:
9068029
19.

Small joint synovitis in rheumatoid arthritis: should it be assessed separately?

Hassell AB, Plant MJ, Clarke S, Fisher J, Jones PW, Saklatvala J, Fowler PD, Shadforth MF, Dawes PT.

Br J Rheumatol. 1995 Jan;34(1):51-5.

PMID:
7881839
20.

Measurement and prediction of radiological progression in early rheumatoid arthritis.

Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT.

J Rheumatol. 1994 Oct;21(10):1808-13.

PMID:
7837142

Supplemental Content

Loading ...
Support Center